Wed, Jul 23, 2014, 5:22 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • venus537 venus537 Nov 14, 2012 7:45 PM Flag

    Exclusivity, NCEs patents, generics..

    "Continuing with having to shoot down the opinions (not facts) made by other media contributors, patent data and information is ABSOLUTELY 100% considered by FDA when examining chemical entities, especially when they are comparing different products head to head -- whether for or against NCE, this data is essential. If AMRN has additional patent data, it would be considered if they allow to accept it."

    From Rosenman's article that nm1066 was referring to.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • venus....

      So Rossman is "shooting down opinions" by others...To post his 100% fact...LOL...I would be a lot more impressed if he told me he was an active member of the FDA's CDER.

      I have had one scheduled meeting with the FDA regarding a medical device. My partner and I sat at a conference table with representatives of the different intra-agency departments. These included medical, legal, compliance, safety and a couple more I do not remember. What I do remember was the obvious scarcely concealed hostility between the department heads.This was related to turf...How does this relate to Rossman ABSOLUTELY 100%..? Well..the H-W defines an NCE in terms of the FDAs APIs...an NCE being defined as a chemical entity that has no active moiety that has been approved by the FDA in any other application...This is determination of the NCE is made by the FDA's CDER committee. Their decisions can be more subjective than the strict definition provided bi H-W, but CDER is the sole determiner and my personal experience would leave me to doubt they bring in even outside members of FDA into the discussions, and certainly not the PTO...THis is MHO...The subjectivity would take in earlier decisions by the FDA...but the point is this is an FDA thing, and not a PTO thing...

      Finally IMHO the NCE is not really very important anyway...

      ": ) JL

      ": ) JL

      Sentiment: Strong Buy

      • 1 Reply to jesse.livermore
      • Thanks for taking time out to comment ( again)

        in regards to NCE, I believe once the NCE drama is behind us the concensus will be squarely behind you
        The value of Amarin's patent portfolio is growing . We wil have 3 new patents issued over the next 3 weeks

        On 11/20 408 will be issued

        On 11/27 145 will be issued

        On 12/4 - 150 will be issued

        Also, 496 (cont. of 885) has already been allowed

        the super patent 520 Anchor is follwoing same course as 889 with Dr. Bays weighing in with his affidavit on unexpected results - same examiner as 889 so I see thsi being allwoed within 2 months or less

        we are in fantastic shape with 8 patents already and 28 more in the pipe

        Sentiment: Strong Buy

 
AMRN
1.580.00(0.00%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.